Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Trial Identifier: 3475-355
Sponsor: MSD
Start Date: July 2016
Primary Completion Date: June 2021
Study Completion Date: October 2023
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary - LA Portuguese
Results Plain Language Summary - EMEA French
Results Plain Language Summary - EMEA Turkish
Results Plain Language Summary - LA Spanish
Results Plain Language Summary - EMEA Polish
Results Plain Language Summary - EMEA Russian
Results Plain Language Summary - EMEA Danish
Results Plain Language Summary - EMEA German (Belgium)
Results Plain Language Summary - EMEA Italian
Results Plain Language Summary - EMEA Dutch (Belgium)
Results Plain Language Summary - EMEA Spanish (Spain)
Results Plain Language Summary - EMEA Hungarian
Results Plain Language Summary - NA Canadian French
Results Plain Language Summary - EMEA German
Results Plain Language Summary - English
Results Plain Language Summary - EMEA Czech
Results Plain Language Summary - EMEA Ukrainian
Results Plain Language Summary - EMEA French (Belgium)

Trial Locations

No locations posted.